Ulcerative Colitis

Investigators discover vedolizumab induces endoscopic remission in 33% of Crohn’s disease patients and histologic remission in 66% of patients after 52 weeks.

Recent measures in the UK has led to a drop in IBD patients using corticosteroids to excess.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.

The FDA-approved drug targets IBS-C patients by increasing bowel movements, while lowering abdominal pain.

In an extensive population-based study, investigators link children with IBD with an increased risk of any psychiatric disorder.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

A further examination of data from a research clinical database shows the risk of smoking outweigh any potential benefits for UC patients.

New evidence from a cumulative RCT analysis suggests irritable bowel syndrome patients do not definitively benefit from FMT treatment.